Published in Nature on September 18, 1997
A third-generation lentivirus vector with a conditional packaging system. J Virol (1998) 16.07
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Cas9 as a versatile tool for engineering biology. Nat Methods (2013) 6.87
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
Diffusion of macromolecules in agarose gels: comparison of linear and globular configurations. Biophys J (1999) 3.26
Herpes simplex virus triggers and then disarms a host antiviral response. J Virol (2001) 2.82
Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol (2002) 2.55
Efficient active transport of gene nanocarriers to the cell nucleus. Proc Natl Acad Sci U S A (2003) 2.52
High-titer human immunodeficiency virus type 1-based vector systems for gene delivery into nondividing cells. J Virol (1998) 2.47
Cascades of transient pores in giant vesicles: line tension and transport. Biophys J (2003) 2.19
Frequency and stability of chromosomal integration of adenovirus vectors. J Virol (1999) 2.18
Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med (2005) 2.10
A Rev-independent human immunodeficiency virus type 1 (HIV-1)-based vector that exploits a codon-optimized HIV-1 gag-pol gene. J Virol (2000) 2.00
Enhancing polyethylenimine's delivery of plasmid DNA into mammalian cells. Proc Natl Acad Sci U S A (2002) 2.00
Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A (1998) 1.93
Recombinant adeno-associated virus vector: use for transgene expression and anterograde tract tracing in the CNS. Brain Res (1998) 1.84
Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: implications for gene therapy. Proc Natl Acad Sci U S A (1998) 1.76
Suppression of angiogenesis by lentiviral delivery of PEX, a noncatalytic fragment of matrix metalloproteinase 2. Proc Natl Acad Sci U S A (2000) 1.76
Controlling integration specificity of a yeast retrotransposon. Proc Natl Acad Sci U S A (2003) 1.74
Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells. J Virol (1998) 1.72
Targeting lentiviral vectors to specific cell types in vivo. Proc Natl Acad Sci U S A (2006) 1.71
Noninvasive imaging of lentiviral-mediated reporter gene expression in living mice. Mol Ther (2003) 1.62
An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J Virol (1999) 1.61
The cHS4 insulator increases the probability of retroviral expression at random chromosomal integration sites. J Virol (2000) 1.60
Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol (2000) 1.57
The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol Ther (2010) 1.55
Long-term correction of diabetes in rats after lentiviral hepatic insulin gene therapy. Diabetologia (2007) 1.53
Adenoviral-mediated gene transfer in lymphocytes. Proc Natl Acad Sci U S A (1998) 1.51
Targeting CREB for cancer therapy: friend or foe. Curr Cancer Drug Targets (2010) 1.49
Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types. Proc Natl Acad Sci U S A (1999) 1.48
A packaging cell line for lentivirus vectors. J Virol (1999) 1.48
Recent advances in nonviral vectors for gene delivery. Acc Chem Res (2011) 1.48
Novel biodegradable poly(disulfide amine)s for gene delivery with high efficiency and low cytotoxicity. Bioconjug Chem (2008) 1.43
Molecular mechanism for silencing virally transduced genes involves histone deacetylation and chromatin condensation. Proc Natl Acad Sci U S A (2000) 1.42
Adeno-associated virus gene repair corrects a mouse model of hereditary tyrosinemia in vivo. Hepatology (2010) 1.41
The relationship between terminal functionalization and molecular weight of a gene delivery polymer and transfection efficacy in mammary epithelial 2-D cultures and 3-D organotypic cultures. Biomaterials (2010) 1.37
Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction. Nucleic Acids Res (2002) 1.37
Amphiphilic block copolymers enhance cellular uptake and nuclear entry of polyplex-delivered DNA. Bioconjug Chem (2008) 1.31
Development of multigene and regulated lentivirus vectors. J Virol (2000) 1.30
A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials (2008) 1.30
Mandibular repair in rats with premineralized silk scaffolds and BMP-2-modified bMSCs. Biomaterials (2009) 1.29
Site-specific integration in mammalian cells mediated by a new hybrid baculovirus-adeno-associated virus vector. J Virol (1998) 1.28
Baculovirus infection of nondividing mammalian cells: mechanisms of entry and nuclear transport of capsids. J Virol (2001) 1.26
Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta (2006) 1.25
A novel assay for quantifying the number of plasmids encapsulated by polymer nanoparticles. Small (2011) 1.25
Induction of angiogenesis in tissue-engineered scaffolds designed for bone repair: a combined gene therapy-cell transplantation approach. Proc Natl Acad Sci U S A (2008) 1.25
Efficient transduction of neural cells in vitro and in vivo by a baculovirus-derived vector. Proc Natl Acad Sci U S A (2000) 1.22
Genetically engineered macrophages expressing IFN-gamma restore alveolar immune function in scid mice. Proc Natl Acad Sci U S A (2001) 1.20
Fusion proteins consisting of human immunodeficiency virus type 1 integrase and the designed polydactyl zinc finger protein E2C direct integration of viral DNA into specific sites. J Virol (2004) 1.20
Activation of CMV promoter-controlled glycosyltransferase and beta -galactosidase glycogenes by butyrate, tricostatin A, and 5-aza-2'-deoxycytidine. Glycoconj J (2005) 1.17
Amelioration of retroviral vector silencing in locus control region beta-globin-transgenic mice and transduced F9 embryonic cells. J Virol (1999) 1.15
Silk-elastinlike recombinant polymers for gene therapy of head and neck cancer: from molecular definition to controlled gene expression. J Control Release (2009) 1.15
Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve (2013) 1.14
Gene delivery from replication-selective viruses: arming guided missiles in the war against cancer. J Clin Invest (2000) 1.13
Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J Virol (1999) 1.13
Structure-activity relationships of cationic shell-crosslinked knedel-like nanoparticles: shell composition and transfection efficiency/cytotoxicity. Biomaterials (2009) 1.11
Nanovehicular intracellular delivery systems. J Pharm Sci (2008) 1.10
A family of bioreducible poly(disulfide amine)s for gene delivery. Biomaterials (2009) 1.10
RB-mediated suppression of spontaneous multiple neuroendocrine neoplasia and lung metastases in Rb+/- mice. Proc Natl Acad Sci U S A (1999) 1.10
Stability without a centromere. Proc Natl Acad Sci U S A (1998) 1.09
Dendrimers as drug delivery vehicles: non-covalent interactions of bioactive compounds with dendrimers. Polym Int (2007) 1.07
Import of DNA into mammalian nuclei by proteins originating from a plant pathogenic bacterium. Proc Natl Acad Sci U S A (1999) 1.07
Neural stem cells as engraftable packaging lines can mediate gene delivery to microglia: evidence from studying retroviral env-related neurodegeneration. J Virol (1999) 1.07
Poisson-Boltzmann theory for membranes with mobile charged lipids and the pH-dependent interaction of a DNA molecule with a membrane. Biophys J (2002) 1.05
RNAi for treating hepatitis B viral infection. Pharm Res (2007) 1.05
Triazine dendrimers as nonviral gene delivery systems: effects of molecular structure on biological activity. Bioconjug Chem (2009) 1.03
Gene therapy imaging in patients for oncological applications. Eur J Nucl Med Mol Imaging (2005) 1.01
A model for intracellular trafficking of adenoviral vectors. Biophys J (2005) 1.00
Well-defined cationic shell crosslinked nanoparticles for efficient delivery of DNA or peptide nucleic acids. Proc Am Thorac Soc (2009) 0.99
Group II intron-based gene targeting reactions in eukaryotes. PLoS One (2008) 0.98
Silk-elastinlike protein polymer hydrogels for localized adenoviral gene therapy of head and neck tumors. Biomacromolecules (2009) 0.98
Visualization of targeted transduction by engineered lentiviral vectors. Gene Ther (2008) 0.97
The use of microbubbles to target drug delivery. Cardiovasc Ultrasound (2004) 0.97
2011 Rita Schaffer lecture: nanoparticles for intracellular nucleic acid delivery. Ann Biomed Eng (2012) 0.97
Real-time functional imaging for monitoring miR-133 during myogenic differentiation. Int J Biochem Cell Biol (2009) 0.96
Highly effective gene transfection in vivo by alkylated polyethylenimine. J Drug Deliv (2011) 0.96
Transcriptional targeting of lentiviral vectors by long terminal repeat enhancer replacement. J Virol (2002) 0.96
Characterization and real-time imaging of gene expression of adenovirus embedded silk-elastinlike protein polymer hydrogels. Mol Pharm (2008) 0.96
Kinetically controlled cellular interactions of polymer-polymer and polymer-liposome nanohybrid systems. Bioconjug Chem (2011) 0.96
Hematopoietic stem cell gene therapy for the multisystemic lysosomal storage disorder cystinosis. Mol Ther (2012) 0.96
Natural killer cell-mediated lysis of autologous cells modified by gene therapy. J Exp Med (1999) 0.95
Baculovirus GP64-mediated entry into mammalian cells. J Virol (2011) 0.95
Synergetic Targeted Delivery of Sleeping-Beauty Transposon System to Mesenchymal Stem Cells Using LPD Nanoparticles Modified with a Phage-Displayed Targeting Peptide. Adv Funct Mater (2013) 0.95
The significance of controlled conditions in lentiviral vector titration and in the use of multiplicity of infection (MOI) for predicting gene transfer events. Genet Vaccines Ther (2004) 0.95
Differential polymer structure tunes mechanism of cellular uptake and transfection routes of poly(β-amino ester) polyplexes in human breast cancer cells. Bioconjug Chem (2013) 0.94
Simian virus 40-based replication of catalytically inactive human immunodeficiency virus type 1 integrase mutants in nonpermissive T cells and monocyte-derived macrophages. J Virol (2004) 0.94
Polymeric carriers for gene delivery: chitosan and poly(amidoamine) dendrimers. Curr Pharm Des (2010) 0.94
DNA modification and functional delivery into human cells using Escherichia coli DH10B. Nucleic Acids Res (2003) 0.94
Transcription-controlled gene therapy against tumor angiogenesis. J Clin Invest (2004) 0.94
Diffusion of flexible random-coil dextran polymers measured in anisotropic brain extracellular space by integrative optical imaging. Biophys J (2008) 0.94
Water-soluble fullerene (C60) derivatives as nonviral gene-delivery vectors. Mol Pharm (2008) 0.94
Acquisition of complement resistance through incorporation of CD55/decay-accelerating factor into viral particles bearing baculovirus GP64. J Virol (2010) 0.93
In vivo manipulation of gene expression in non-human primates using lentiviral vectors as delivery vehicles. Methods (2009) 0.92
Influence of polymer structure and biodegradation on DNA release from silk-elastinlike protein polymer hydrogels. Int J Pharm (2008) 0.92
Acid-degradable cationic dextran particles for the delivery of siRNA therapeutics. Bioconjug Chem (2011) 0.92
A new hybrid system capable of efficient lentiviral vector production and stable gene transfer mediated by a single helper-dependent adenoviral vector. J Virol (2003) 0.92
LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives. Int Arch Med (2010) 0.91
Integrase-lexA fusion proteins incorporated into human immunodeficiency virus type 1 that contains a catalytically inactive integrase gene are functional to mediate integration. J Virol (2000) 0.91
In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science (1996) 28.95
Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science (1996) 12.23
Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc Natl Acad Sci U S A (1996) 9.15
Platelet-derived growth factor induces rapid but transient expression of the c-fos gene and protein. Nature (1985) 8.36
Generation of helper-free amphotropic retroviruses that transduce a dominant-acting, methotrexate-resistant dihydrofolate reductase gene. Mol Cell Biol (1985) 7.49
The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol (1996) 6.62
Development of a self-inactivating lentivirus vector. J Virol (1998) 6.60
Severe liver degeneration in mice lacking the IkappaB kinase 2 gene. Science (1999) 6.20
FBJ murine osteosarcoma virus: identification and molecular cloning of biologically active proviral DNA. J Virol (1982) 6.11
Analysis of FBJ-MuSV provirus and c-fos (mouse) gene reveals that viral and cellular fos gene products have different carboxy termini. Cell (1983) 5.79
Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell (1990) 5.59
c-fos protein can induce cellular transformation: a novel mechanism of activation of a cellular oncogene. Cell (1984) 5.55
Nucleotide sequence of the genome of a murine sarcoma virus. Cell (1981) 5.48
Induction of proto-oncogene JUN/AP-1 by serum and TPA. Nature (1988) 5.18
Viral and cellular fos proteins: a comparative analysis. Cell (1984) 4.89
Expression of the c-fos gene and of an fos-related gene is stimulated by platelet-derived growth factor. Science (1984) 4.87
Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus. Nature (1986) 4.70
Expression of cellular oncogenes in human malignancies. Science (1984) 4.48
Differential expression of cellular oncogenes during pre- and postnatal development of the mouse. Nature (1982) 4.44
Complete nucleotide sequence of a human c-onc gene: deduced amino acid sequence of the human c-fos protein. Proc Natl Acad Sci U S A (1983) 4.38
Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat Genet (1997) 4.26
The reverse transcriptase. Biochim Biophys Acta (1977) 4.16
Transcriptional autoregulation of the proto-oncogene fos. Nature (1988) 4.10
Long terminal repeat of murine retroviral DNAs: sequence analysis, host-proviral junctions, and preintegration site. J Virol (1982) 4.06
Nucleotide sequence and formation of the transforming gene of a mouse sarcoma virus. Nature (1981) 4.05
In vitro synthesis of DNA complementary to rabbit reticulocyte 10S RNA. Nat New Biol (1972) 4.01
Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Proc Natl Acad Sci U S A (1995) 3.90
fos-associated cellular p39 is related to nuclear transcription factor AP-1. Cell (1988) 3.82
Rapid induction of the expression of proto-oncogene fos during human monocytic differentiation. Cell (1985) 3.81
Transcriptional activation by BRCA1. Nature (1996) 3.64
Functional antagonism between c-Jun and MyoD proteins: a direct physical association. Cell (1992) 3.55
Structure of Moloney murine leukemia viral DNA: nucleotide sequence of the 5' long terminal repeat and adjacent cellular sequences. Proc Natl Acad Sci U S A (1980) 3.53
The rel-associated pp40 protein prevents DNA binding of Rel and NF-kappa B: relationship with I kappa B beta and regulation by phosphorylation. Genes Dev (1991) 3.52
Direct interaction between fos and jun nuclear oncoproteins: role of the 'leucine zipper' domain. Nature (1988) 3.43
Analysis of the env gene of a molecularly cloned and biologically active Moloney mink cell focus-forming proviral DNA. J Virol (1982) 3.40
Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. Proc Natl Acad Sci U S A (1997) 3.40
Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. J Virol (1997) 3.37
Studies on reverse transcriptase of RNA tumor viruses III. Properties of purified Moloney murine leukemia virus DNA polymerase and associated RNase H. J Virol (1975) 3.31
A transmissible retrovirus expressing human hypoxanthine phosphoribosyltransferase (HPRT): gene transfer into cells obtained from humans deficient in HPRT. Proc Natl Acad Sci U S A (1983) 3.31
Covalently linked RNA-DNA molecule as initial product of RNA tumour virus DNA polymerase. Nat New Biol (1971) 3.27
I kappa B gamma, a 70 kd protein identical to the C-terminal half of p110 NF-kappa B: a new member of the I kappa B family. Cell (1992) 3.25
c-fos promoter trans-activation by the tax1 protein of human T-cell leukemia virus type I. Proc Natl Acad Sci U S A (1988) 3.24
Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity. Proc Natl Acad Sci U S A (2001) 3.24
Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci U S A (1994) 3.24
Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science (1999) 3.10
Two base changes restore infectivity to a noninfectious molecular clone of Moloney murine leukemia virus (pMLV-1). J Virol (1984) 3.09
Removal of a 67-base-pair sequence in the noncoding region of protooncogene fos converts it to a transforming gene. Proc Natl Acad Sci U S A (1985) 2.95
Regulated mRNA stability. Annu Rev Genet (1990) 2.93
IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev (1999) 2.92
Nucleotide sequence of Moloney leukemia virus: 3' end reveals details of replications, analogy to bacterial transposons, and an unexpected gene. Proc Natl Acad Sci U S A (1980) 2.90
Viral and cellular fos proteins are complexed with a 39,000-dalton cellular protein. Mol Cell Biol (1985) 2.86
Retinoic acid is a negative regulator of AP-1-responsive genes. Proc Natl Acad Sci U S A (1991) 2.85
Nuclear proto-oncogenes fos and jun. Annu Rev Cell Biol (1990) 2.82
Heteroduplex analysis of the sequence relations between the RNAs of mink cell focus-inducing and murine leukemia viruses. J Virol (1978) 2.79
Expression cloning of human EGF receptor complementary DNA: gene amplification and three related messenger RNA products in A431 cells. Science (1984) 2.75
Induction of the proto-oncogene fos by nerve growth factor. Proc Natl Acad Sci U S A (1985) 2.74
M-MuLV-induced leukemogenesis: integration and structure of recombinant proviruses in tumors. Cell (1981) 2.65
c-rel activates but v-rel suppresses transcription from kappa B sites. Proc Natl Acad Sci U S A (1991) 2.65
Gene therapy: trials and tribulations. Nat Rev Genet (2000) 2.62
Studies on the reverse transcriptase of RNA tumor viruses. Structural relatedness of two subunits of avian RNA tumor viruses. Proc Natl Acad Sci U S A (1974) 2.60
Cationic liposome-mediated RNA transfection. Proc Natl Acad Sci U S A (1989) 2.55
Structure of the FBJ murine osteosarcoma virus genome: molecular cloning of its associated helper virus and the cellular homolog of the v-fos gene from mouse and human cells. Mol Cell Biol (1983) 2.53
Expression of a retrovirus encoding human HPRT in mice. Science (1984) 2.48
Delivery of the Cre recombinase by a self-deleting lentiviral vector: efficient gene targeting in vivo. Proc Natl Acad Sci U S A (2001) 2.48
The mouse c-rel protein has an N-terminal regulatory domain and a C-terminal transcriptional transactivation domain. Mol Cell Biol (1990) 2.47
Modification of fos proteins: phosphorylation of c-fos, but not v-fos, is stimulated by 12-tetradecanoyl-phorbol-13-acetate and serum. Mol Cell Biol (1987) 2.40
Identification of a transcriptional enhancer element upstream from the proto-oncogene fos. Science (1985) 2.39
Induction of proto-oncogene fos transcription through the adenylate cyclase pathway: characterization of a cAMP-responsive element. Genes Dev (1988) 2.38
mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. Mol Cell Biol (1990) 2.38
Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci U S A (1991) 2.34
Gene therapy via primary myoblasts: long-term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci U S A (1992) 2.30
Direct association of pp40/I kappa B beta with rel/NF-kappa B transcription factors: role of ankyrin repeats in the inhibition of DNA binding activity. Proc Natl Acad Sci U S A (1992) 2.29
Detection of a transforming gene product in cells transformed by Moloney murine sarcoma virus. Cell (1982) 2.27
A factor IX-deficient mouse model for hemophilia B gene therapy. Proc Natl Acad Sci U S A (1997) 2.22
Identification of a RNA polymerase II initiation site in the long terminal repeat of Moloney murine leukemia viral DNA. Proc Natl Acad Sci U S A (1981) 2.16
Transcription of c-onc genes c-rasKi and c-fms during mouse development. Mol Cell Biol (1983) 2.14
Tumor necrosis factor alpha-induced phosphorylation of I kappa B alpha is a signal for its degradation but not dissociation from NF-kappa B. Proc Natl Acad Sci U S A (1994) 2.12
Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther (2000) 2.12
Both the basic region and the 'leucine zipper' domain of the cyclic AMP response element binding (CREB) protein are essential for transcriptional activation. EMBO J (1990) 2.11
Molecular cloning of unintegrated and a portion of integrated moloney murine leukemia viral DNA in bacteriophage lambda. J Virol (1980) 2.10
Role of Rel/NF-kappaB transcription factors during the outgrowth of the vertebrate limb. Nature (1998) 2.08
Expression of c-onc genes: c-fos transcripts accumulate to high levels during development of mouse placenta, yolk sac and amnion. EMBO J (1983) 2.08
Fos-Jun interaction: mutational analysis of the leucine zipper domain of both proteins. Genes Dev (1989) 2.06
Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol (2000) 2.04
BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc Natl Acad Sci U S A (1997) 2.02
Identification and molecular cloning of Moloney mouse sarcoma virus-specific sequences from uninfected mouse cells. Proc Natl Acad Sci U S A (1980) 1.98
Complete lack of NF-kappaB activity in IKK1 and IKK2 double-deficient mice: additional defect in neurulation. Genes Dev (2000) 1.96
Association between proto-oncoprotein Rel and TATA-binding protein mediates transcriptional activation by NF-kappa B. Nature (1993) 1.94
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci U S A (1999) 1.90
Size analysis and relationship of murine leukemia virus-specific mRNA's: evidence for transposition of sequences during synthesis and processing of subgenomic mRNA. J Virol (1978) 1.90
DNA polymerase activity from two temperature-sensitive mutants of Rous sarcoma virus is thermolabile. Nature (1974) 1.90
Qualitative changes in the subunit composition of kappa B-binding complexes during murine B-cell differentiation. Proc Natl Acad Sci U S A (1994) 1.89
c-fos expression is neither sufficient nor obligatory for differentiation of monomyelocytes to macrophages. Cell (1986) 1.87
Thermolabile reverse transcriptase of a mammalian leukemia virus mutant temperature sensitive in its replication and sarcoma virus helper functions. J Virol (1975) 1.87
Studies on reverse transcriptase of RNA tumor viruses. I. Localization of thermolabile DNA polymerase and RNase H activities on one polypeptide. J Virol (1975) 1.84
Inhibition of TNF-induced apoptosis by NF-kappa B. Trends Cell Biol (1998) 1.84
Rel/NF-kappa B/I kappa B story. Adv Cancer Res (1995) 1.83
Modulation of c-fos gene transcription by negative and positive cellular factors. Nature (1987) 1.83
Gene therapy: promises and problems. Annu Rev Genomics Hum Genet (2001) 1.82
Phosphorylation of the C terminus of Fos protein is required for transcriptional transrepression of the c-fos promoter. Nature (1990) 1.81